CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today...
Hence then, the article about harbour biomed reports the online publication of phase i results for hbm9378 skb378 win378 a tslp targeting antibody was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody )
Also on site :
- Deye 2026 Frankfurt Distributor & Partner Summit Concludes Successfully
- Iranians Fear Trump’s Threat to Strike Power Plants
- Crimson Desert patch 1.00.03 addresses storage issues, Keyboard & mouse controls & more